Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on N...
03 Novembre 2020 - 3:20PM
via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA)
(“Processa” or the “Company”), a clinical-stage biopharmaceutical
company developing products to improve survival and/or quality of
life for patients who have high unmet medical need conditions,
today announces it will host a conference call and live webcast on
Nov. 12, 2020, at 5:30 p.m. Eastern time to discuss its third
quarter 2020 results and provide an update on the Company’s
clinical pipeline. The update will include a discussion of the
Company’s three clinical-stage drugs (each of which addresses
potential billion-dollar markets):
1) PCS6422 combined with fluoropyrimidines to treat
multiple types of cancers.
2) PCS499 to treat ulcerated necrobiosis lipoidica,
a rare orphan condition.
3) PCS12852 to treat GI motility conditions such as
gastroparesis, the approved drugs and off-label-use drugs for which
have caused very serious side effects.
Q&A with CEO David Young and the management team will take
place at the conclusion of the call.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Date: Nov. 12, 2020 Time: 5:30 p.m. ET Dial-In
Information: Toll Free: 877-876-9176 International:
785-424-1670
Live Webcast:
https://www.webcaster4.com/Webcast/Page/2572/38528
Conference Call Replay Information
Toll-free: 877-481-4010 International: 919-882-2331 Replay
Passcode: 38528
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products for which
existing clinical evidence of efficacy has already been established
for unmet or underserved medical conditions for which patients need
treatment options that improve survival and or quality of life. The
Company used these criteria to develop its pipeline programs in
order to effectively and efficiently achieve high-value milestones
using the Processa Regulatory Science approach. The members of the
Processa development team have been involved with more than 30 drug
approvals by the FDA (including drug products targeted to orphan
disease conditions) and more than 100 FDA meetings throughout their
careers.
For more information, visit the company’s website
at www.ProcessaPharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements
in this press release that are not purely historical are
forward-looking statements that involve risks and uncertainties.
Actual future performance outcomes and results may differ
materially from those expressed in forward-looking statements.
Please refer to the documents filed by Processa Pharmaceuticals
with the SEC, specifically the most recent reports on Forms 10-K
and 10-Q, which identify important risk factors that could cause
actual results to differ from those contained in the
forward-looking statements.
For More Information: Michael Floyd (301) 651-4256
mfloyd@processapharma.com
James Carbonara Hayden IR (646) 755-7412 james@haydenir.com
Corporate Communications:InvestorBrandNetwork
(IBN) Los Angeles, California www.InvestorBrandNetwork.com
310.299.1717 Office Editor@InvestorBrandNetwork.com
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024